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Aspirin compared to enoxaparin or rivaroxaban for thromboprophylaxis following hip 2 
and knee replacement. 3 
Abstract 4 
Background: The risk of venous thromboembolism following major orthopaedic 5 
surgery is among the highest for all surgical specialties. Our hospital guidelines for 6 
thromboprophylaxis following elective primary total hip or knee replacement are 7 
based on American College of Chest Physicians guidance. The most recent change to 8 
local guidelines was the introduction of the extended aspirin regimen as standard 9 
thromboprophylaxis.  10 
Objective: To establish the appropriateness of this regimen by comparing venous 11 
thromboembolism rates in patients receiving extended aspirin to previous regimens. 12 
Setting: The largest dedicated orthopaedic hospital in Ireland 13 
Methods: This was a retrospective cohort study. Data were collected from patient 14 
record software. All eligible patients undergoing primary total hip or knee replacement 15 
between 1st January 2010 and 30th June 2016 were included.  16 
Main Outcome Measure: Venous thromboembolism up to six months post-17 
operatively. 18 
Results: Of the 6,548 participants (55.3% female, mean age 65.4 years (± 11.8 years, 19 
55.8% underwent total hip replacement), venous thromboembolism occurred in 65 20 
(0.99%). Venous thromboembolism rate in both the inpatient enoxaparin group 21 
(n=961) and extended aspirin group (n=3,460) was 1.04% and was 0.66% in the 22 
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modified rivaroxaban group (n=1,212). Non-inferiority analysis showed the extended 23 
aspirin regimen to be equivalent to the modified rivaroxaban regimen. History of 24 
venous thromboembolism was the only significant demographic risk factor for post-25 
operative venous thromboembolism (0.87% vs. 3.54%, p=0.0002).  26 
Conclusion: In daily clinical practice, extended aspirin regimen is at least as effective 27 
as modified rivaroxaban for preventing clinically important venous thromboembolism 28 
among patients undergoing hip or knee arthroplasty who are discharged from the 29 
hospital without complications. Aspirin can be considered a safe and effective agent 30 
in the prevention of venous thromboembolism after total hip or total knee replacement. 31 
Impact of findings on practice 32 
• The findings of this study, along with other emerging evidence, is pertinent to 33 
Clinical Pharmacists when advising on patient care and developing local 34 
guidelines on VTE prophylaxis. 35 
• This study should encourage future work to establish the efficacy of aspirin for 36 
VTE prophylaxis in a robust RCT setting, and also to investigate potential 37 
benefits in reducing bleeding complications. 38 
• Aspirin thromboprophylaxis may offer a cost-effective alternative to 39 
practitioners who may fear non-adherence to therapy in their patients due to 40 
financial difficulties. 41 
 42 
Key Words 43 




Main Text 46 
Introduction 47 
The American College of Chest Physicians (ACCP) have calculated the cumulative 48 
rate of non-fatal symptomatic VTE in the first 35 days after surgery as 1.8% in patients 49 
treated with low-molecular-weight heparin (LMWH) and 4.3% in untreated patients 50 
[1]. Reported symptomatic VTE rates with aspirin or multimodal aspirin regimens 51 
range from 0.1%-4.17% [2-12], with rivaroxaban range from 0.47%-1.4% [13, 14, 10, 52 
15, 11] and with enoxaparin range from 0.65%-2.5% [13, 5, 15].   53 
Until recently, the evidence supporting the effectiveness of aspirin in this setting is 54 
based mainly on observational and registry studies [1]. Evidence is now emerging 55 
from randomised controlled trials (RCTs), most notably the EPCAT-1 and EPCAT-2 56 
trials [11, 2]. The National Institute for Health and Care Excellence (NICE) updated 57 
their guidelines in March 2018 and now include aspirin as an option for VTE 58 
prophylaxis following elective total hip replacement (THR) and total knee 59 
replacement (TKR) [16]. In contrast, a recent Australian Evidence Review [17]  found 60 
the evidence to be equivocal with regard to aspirin for VTE prophylaxis.  61 
Guidelines in our hospital in use at the time of the study were based on ACCP guidance 62 
[1]. A timeline of the changes to local guidance can be seen in Table 1. The current 63 
standard thromboprophylaxis regimen in the hospital is the extended aspirin regimen.  64 
Aim of the Study 65 
To establish whether aspirin is an appropriate agent for thromboprophylaxis in our 66 
patient population by comparing the rate of VTE six months’ post-surgery in patients 67 
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receiving extended aspirin to those receiving the previous regimens of inpatient 68 
enoxaparin or the modified rivaroxaban regimen. 69 
Ethics Approval 70 
Ethical approval was granted by the hospital Ethics Committee (reference 71 
CAPP/2017/ETH/SH-DCEO-0021).  72 
Methods 73 
The study site is the largest dedicated orthopaedic hospital in Ireland, with 2,717 74 
inpatients admitted in 2016, and specialises in elective arthroplasty. The Joint Register 75 
was established in our hospital in 2004, and its purpose is to record and monitor post-76 
operative outcomes, including VTE [18]. 77 
This is a retrospective cohort study, whereby patients were grouped according to the 78 
type of thromboprophylaxis prescribed. The rate of VTE in each group was the 79 
outcome of interest.  80 
Inclusion and Exclusion Criteria 81 
An interval sampling method was used whereby all patients who underwent elective 82 
primary TKR or THR within the study period, 1st January 2010 to 30th June 2016, were 83 
included. Each surgery represented one unit of study; if a patient underwent more than 84 
one procedure during the study period, they appeared more than once in the dataset. 85 
Patients were excluded if: 86 
• Their surgery was cancelled after admission. 87 
• They did not attend their six-month Joint Register appointment (as the required 88 
information was not available for these patients).  89 
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Data were collected from Bluespier®; the hospital’s electronic patient record software. 90 
It was determined whether participants developed a VTE using their electronic file. 91 
Pre-discharge VTE was recorded as an inpatient complication by a clinician. Post-92 
discharge VTE was recorded on the report generated at the six-month Joint Register 93 
review. 94 
The data were exported as a Microsoft Excel® report, cleaned and pseudonymised. 95 
Patients were allocated to a thromboprophylaxis group on an intention to treat (ITT) 96 
basis, according to the instructions in their Theatre notes, discharge letter or discharge 97 
prescription.  98 
Statistical methods 99 
Treatment group allocation was on an ITT basis, and this is similar to the approach 100 
taken in a clinical trial setting. A similar approach was used in Hamilton et al’s study 101 
[4].  102 
Categorical patient characteristics were described by their counts and percentages in 103 
each category. Continuous characteristics were described by their means and SDs, 104 
medians and IQRs, and total ranges. 105 
VTE rates and 95% confidence intervals (CIs) were estimated using Poisson 106 
regression. 107 
We evaluated the equivalence (and thus non-inferiority) of the Extended aspirin 108 
regimen to Modified rivaroxaban regimen based on the risk difference for VTE, using 109 
a margin of ±1.0%. The authors were confident that the ±1.0% margin of difference 110 
in the rate of outcome (VTE) between regimens would represent clinical acceptability 111 
and is supported by Wilson et al [19]. We reported both the unadjusted and adjusted 112 
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risk differences and respective 90% confidence intervals (which is the equivalent of 113 
two one-sided tests [TOST], each with alpha = 0.05 [20]. Covariate adjustment was 114 
made using the standardized risk difference estimated with a marginal structural 115 
binomial regression model [21]. The covariates were age (years), sex, body mass index 116 
(BMI kg/m2), any history of VTE (none vs Deep Vein Thrombosis [DVT] vs 117 
Pulmonary Embolism [PE]), and procedure (TKR vs THR). Patients with missing 118 
covariate data were excluded from the adjusted risk difference models. 119 
In addition to the head to head comparison between Modified rivaroxaban regimen 120 
and Enoxaparin, then aspirin and we similarly evaluated the equivalence in the VTE 121 
risk difference between patients seen from 2010 to 2012 and those seen from 2013 to 122 
2016, irrespective of the actual VTE prophylaxis received. This was because the 123 
Extended aspirin regimen was almost always used from 2013 on, and very rarely used 124 
before 2013 (see supplemental figure 1). 125 
All analysis were conducted using the R Project for Statistical Computing v3.4.3 [22]  126 
Results 127 
Of the 6,945 patients admitted  during the study period, 6,548 (55.3% female, 55.8% 128 
THR, mean age was 65.4 years (± 11.8years) and mean BMI was 30.3kg/m2 (± 5.6 129 
kg/m2)) were eligible for inclusion. Reasons for exclusion are shown in Figure 1. 130 
Demographics are outlined in Table 2 with the percentages reported calculated based 131 
upon participants for whom data were available.    132 
Information on the regimen prescribed was available for 6,418 participants (98.01%). 133 
No VTE occurred in patients for whom data on the thromboprophylaxis regimen 134 
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prescribed were missing. The proportion of participants allocated to each treatment 135 
group is summarised in Table 2. 136 
Sixty-five participants had a VTE (0.99% of 6,548). VTE rates and 95% CIs across 137 
study all years are given in Figure 2. The unadjusted VTE risk difference comparing 138 
the Extended aspirin regimen to Modified rivaroxaban regimen (n = 4,673) was 0.38% 139 
with a 90% TOST CI of -0.096% to 0.86%, which suggests equivalence between the 140 
two (i.e. the CI falls within the margin interval of ± 1%).  141 
The unadjusted VTE risk difference comparing patients seen in 2010-2012 (inpatient 142 
enoxaparin, rivaroxaban or modified rivaroxaban) to those seen in 2013-2016 143 
(extended aspirin) was 0.12% with a 90% TOST CI of -0.28% to 0.52%, suggesting 144 
equivalence in VTE risk between the two time periods (n = 6548).  145 
In demographic analysis, history of VTE was identified as the only statistically and 146 
clinically significant risk factor for post-operative VTE (0.87% vs. 3.54%, p=0.0002). 147 
The results were not appreciably different in those with a history of VTE vs those 148 
without (though our study would not have been well-powered to detect any clinically 149 
meaningful differences, given that only 5% of our sample had a history of VTE). A 150 
history of PE was associated with an increased risk of post-operative VTE (0.87% vs. 151 
5.56%, p=0.0004). The increase in risk was not as large with a history of DVT but was 152 
statistically significant (0.87% vs. 2.46% p=0.037). When history of VTE was 153 
adjusted for other demographic variables (age, sex and BMI) the adjusted OR was 3.56 154 
(95% CI 1.77–7.14; p<0.001) for any VTE history, and 2.13 (0.76–6.00; p=0.152) for 155 
DVT and 6.38 (2.66 – 15.32; p<0.001) for PE specifically. 156 
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The VTE rates in the inpatient enoxaparin, modified rivaroxaban and extended aspirin 157 
groups are shown in Table 3. The demographics of each group are detailed in the 158 
supplementary material. 159 
Discussion 160 
The results indicate that, when known confounding factors are accounted for, there 161 
was no significant difference in the effectiveness of these regimens in the prevention 162 
of VTE, therefore the extended aspirin regimen is an appropriate thromboprophylaxis 163 
regimen for our patients. 164 
There was no difference in the incidence of VTE between the extended aspirin and 165 
inpatient enoxaparin groups, with reported VTE rates of 1.04% in both groups. 166 
Additionally, the rates of DVT and PE were almost identical. The rate of VTE in the 167 
modified rivaroxaban group was lower at 0.66%. However, both the adjusted and 168 
unadjusted risk difference between these groups suggests the two treatments are 169 
equivalent. No clinically significant difference existed between the groups, since the 170 
difference in VTE rate between the groups was less than the clinically significant 171 
difference we proposed of 1%. 172 
Reported symptomatic VTE rates with aspirin or multimodal aspirin regimens range 173 
from 0.1%-4.17% [2-12], with rivaroxaban ranging from 0.47%-1.4% [13, 14, 10, 15, 174 
11], and with enoxaparin regimens ranging from 0.65%-2.5% [13, 5, 15]. Our results 175 
fall within the expected range based on these studies.  176 
In keeping with our findings, eight studies found no significant difference in VTE rates 177 
between aspirin and LMWH regimens [2, 3, 5-7, 23-25]. Wilson et al’s recent 178 
systematic review [19] found no evidence of a difference in VTE rates between aspirin 179 
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and LMWH-treated groups. The Pulmonary Embolism Prevention  (PEP) trial [9] used 180 
aspirin 160mg daily, similar to the dose used in our study (150mg daily), and a similar 181 
VTE rate of 1.1% was reported in the aspirin group, as well as similar DVT and PE 182 
rates of 0.73% and 0.39% respectively. A pooled analysis of data from 14 RCTs by 183 
Brown [26] found no statistically significant difference between aspirin and LMWH 184 
regimens, and reported symptomatic DVT rates of 0.96% for aspirin and 1.28% for 185 
LMWH groups (p=0.057, RR 1.33, 95% CI 0.99-1.78), and PE rates of 0.62% for 186 
aspirin and 0.45% for LMWH groups (p=0.13, RR 0.73, 95% CI 0.49-1.09). In 187 
comparison, DVT rates were lower in our study and PE rates were similar. Anderson 188 
et al’s RCT [2] reported that a multimodal aspirin regimen was non-inferior to LMWH 189 
(AD 1%, 95% CI −0.5-2.5%, p<0.001), though the reported VTE rate in the aspirin 190 
group was much lower than in our study at 0.3%; this may have been due to small 191 
sample size. The meta-analysis conducted by An et al in 2016 [27] concluded that 192 
aspirin, both alone and in multimodal regimens, resulted in a DVT rate of 1.2% and a 193 
PE rate of 0.6%. The DVT rate observed in our study is lower than expected from An 194 
et al’s results, however the PE rate is similar.  195 
The rate of symptomatic VTE in the modified rivaroxaban group is similar to the rate 196 
of 0.5% reported with rivaroxaban in a meta-analysis by Gómez-Outes et al [28]. A 197 
recent RCT by Anderson et al [11], comparing rivaroxaban to a multimodal regimen 198 
of rivaroxaban followed by aspirin (81mg daily), reported a VTE rate of 0.7% and 199 
0.64% in the respective groups, showing non-inferiority of the aspirin regimen (AD 200 
0.06%, 95% CI −0.55-0.66%, p<0.001).  Though the overall VTE rates reported by 201 
Anderson et al are lower than observed in our study, they reach similar conclusions. 202 
Rath et al [10] compared aspirin 150mg daily, the same dose used in our study, to 203 
rivaroxaban. They found a significant reduction in PE rates with rivaroxaban 204 
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(p=0.0084) but no significant difference in symptomatic DVT rates. These are similar 205 
to our findings, where a larger reduction was seen in PE rates compared to DVT rates, 206 
however the difference was not found to be significant in our study. Zou et al [25] 207 
found a much larger difference in DVT rates between aspirin (100mg daily) and 208 
rivaroxaban groups (16.36% vs. 2.94%), and this was statistically significant 209 
(p=0.017). This large difference may be due to (i) the inclusion of asymptomatic DVT 210 
in their outcome measure, which was not included in our study, (ii) the use of a lower 211 
dose of aspirin, or (iii) the small sample size. In their systematic review Wilson et al 212 
[19] found that, compared with aspirin, rates of asymptomatic DVT in TKR were 213 
lower with rivaroxaban. However, they found insufficient evidence to demonstrate an 214 
effect on symptomatic DVT or PE, which are outcomes of clinical importance. 215 
Potential confounding factors were generally well balanced between the groups 216 
investigated by our study, reducing their impact on the comparison of agents. 217 
Additional analysis was completed to account for confounding factors and the adjusted 218 
results were similar to the unadjusted results. The advances in post-operative 219 
management and decrease in length of stay (LOS) over the study period may have had 220 
a positive impact in reducing VTE rates, and this may be a confounding factor in 221 
comparing the inpatient enoxaparin group to the extended aspirin group.  222 
The overall demographics of the study population were similar to that observed in 223 
other studies and registries. The demographic analysis found that a history of VTE 224 
was associated with a four-fold higher risk of post-operative VTE, and the risk in 225 
participants with a history of PE was six times higher than in those without prior VTE, 226 
reflecting the literature [29-33]. This remained the case when history of VTE was 227 
adjusted for other demographics (age, sex and BMI). No other demographic risk factor 228 
was found to be statistically or clinically significant in this study. Just under 5% 229 
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(n=311) of participants had a history of VTE. In other similar studies [2, 34-37, 15, 230 
38] the proportion of patients with a history of VTE ranged from 1.22% [36] to 3.99% 231 
[35]. Some studies excluded these participants [4, 23, 14, 8, 9, 24, 25]. Therefore, 232 
participants in our study may be considered a higher risk population in comparison to 233 
other studies. Since history of VTE was the strongest risk factor for post-operative 234 
VTE in our patients, consideration should be given to those with a prior VTE when 235 
assessing risk and prescribing thromboprophylaxis. Of note, the Australian Evidence 236 
Review on the topic specified that aspirin should only be considered in patients 237 
without major risk factors for VTE or bleeding, therefore patients with a history of 238 
VTE would be excluded [20]. Future research should evaluate differences in treatment 239 
and adverse event effects in relevant subgroups of patients e.g. race/ethnicity, body 240 
weight, tobacco use, presurgical use of antiplatelet drugs or warfarin.  241 
Limitations 242 
As this was an observational study, it was not possible to establish the effectiveness 243 
of the regimen. The possibility of errors occurring in entry of data to Bluespier® by 244 
clinicians cannot be excluded, as the data were not entered specifically for the purpose 245 
of this study. Due to the nature of the data source used, there was a small proportion 246 
of missing data. VTE may have been under-reported, as our study data were collected 247 
retrospectively from a computer database reliant on physician and patient reporting. It 248 
was not possible to determine compliance with thromboprophylaxis post-discharge, 249 
and it was assumed that most participants continued the regimen initially prescribed. 250 
These factors were consistent across the entire study population and should not 251 
influence the comparison of outcomes between treatment groups. Other confounding 252 
factors not recorded on the electronic record, such as inflammatory state, 253 
haematological disorders and malignancy, could not be included for when adjusting 254 
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the results to account for demographics. There were no data available on bleeding rates 255 
with the regimens used in the study, therefore this should be investigated in future 256 
research.  257 
Conclusion 258 
It can be concluded that the extended aspirin regimen is appropriate for 259 
thromboprophylaxis following elective primary TKR and THR. There was no 260 
difference between the extended aspirin and inpatient enoxaparin groups, which both 261 
had VTE rates of 1.04%. The modified rivaroxaban group had a lower VTE rate of 262 
0.66%, but the difference in comparison with the extended aspirin group was not 263 
statistically significant and was not considered clinically significant.  264 
This study identified an overall low VTE rate of 0.99% in our patient population. 265 
History of VTE was identified as a strong independent risk factor for post-operative 266 
VTE, particularly PE, and this was statistically and clinically significant. No other 267 
significant risk factors were identified. 268 
The findings of this study have implications locally in confirming the equivalence of 269 
our current standard thromboprophylaxis regimen to previously used regimens. This 270 
study adds to the growing evidence supporting the use of aspirin for 271 
thromboprophylaxis in the orthopaedic setting. Aspirin may be particularly 272 
advantageous in terms of cost-saving and accessibility. 273 
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Table 1:  Thromboprophylaxis Regimens in CNOH 
 










ACCP guidance with 
limited oral alternatives [39] 
Enoxaparin 40mg OD 
commenced 12 hours post-










Introduction of DOACs to 
market 
 
Implementation of ACCP 






commenced 6-10 hours 
post-operatively, and 
continued for 14 days 





Reports of wound 
complications with 
rivaroxaban regimen locally 
and in literature [40, 41] 
 
Enoxaparin 40mg OD 
commenced 12 hours post-
operatively for three doses, 
followed by rivaroxaban 
10mg OD for 14 days 








Reports of major bleeding 
with modified rivaroxaban 
regimen locally 
 
ACCP guidance on aspirin 
[1] 
 
Enoxaparin 40mg OD 
commenced 12 hours post-
operatively for three doses, 
followed by aspirin 150mg 
OD for 28 days 









Table 2 : Demographics of Study Population 





Sex 6548    
Males  2928 
(44.7%) 
  
Female  3620 
(55.3%) 
  
Age (years) 6548 65.4 ± 11.8 66 (58, 74) (13, 95) 
65+ years 6548    
No  2829 
(43.2%) 
  
Yes  3719 
(56.8%) 
  
BMI (kg/m2) 6173 30.3 ± 5.6 30 (26, 34) (13, 51) 
Obese (BMI ≥30kg/m2) 6173    
No  2950 
(47.8%) 
  
Yes  3223 
(52.2%) 
  
Length of stay (days) 6548 5.9 ± 10.3 5 (4, 7) (0, 522) 
Procedure 6548    
TKR  2897 
(44.2%) 
  
THR  3651 
(55.8%) 
  
VTE type 6548    
None  6483 (99%)   
DVT before discharge  4 (0.1%)   
PE before discharge  14 (0.2%)   
DVT at 6 months  28 (0.4%)   
PE at 6 months  19 (0.3%)   
Anticoagulant 6225    
None  3971 
(63.8%) 
  
Aspirin  1810 
(29.1%) 
  
Other  444 (7.1%)   
History of VTE 6265    
None  5954 (95%)   
DVT  203 (3.2%)   
PE  108 (1.7%)   
VTE prophylaxis 6418    
Extended aspirin regimen  3460 
(53.9%) 
  






Other*  785 (12.2%)   
 
*The majority of this group consisted of patients taking regular anticoagulants or antiplatelets other 
than aspirin who resumed their usual medications in place of a standard regimen. A small proportion 
consisted of patients who received rivaroxaban as per product licence. 
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Table 3 Rates of VTE in Treatment Group 
 
*compared to extended aspirin 
Thromboprophylaxis Regimen Number 
in 
Group 
VTE n (%) 








PE at Joint 
Register 
Inpatient Enoxaparin Regimen 
(up to 2010) 
961 10 (1.04%) 5 (0.52%) 5 (0.52%) 1 (0.10%) 3 (0.31%) 4 (0.42%) 2 (0.21%) 
Modified Rivaroxaban 
Regimen (2010-2012) 




4 (0.33%) 0 (0%) 2 (0.17%) 
 
4 (0.33%) 2 (0.17%) 
Extended Aspirin Regimen 
(2013-present) 
3,460 36 (1.04%) 
 
17 (0.49%) 19 (0.55%) 1 (0.03%) 5 (0.14%) 16 (0.46%) 14 (0.40%) 









 Figure 2:  Yearly VTE incidence (with 95% CIs), regardless of VTE prophylaxis.  
 











Did not Attend Joint 
Register Review  
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